Advanced Biomed

As of March 31, 2026, cash was about $2.60 million and total liabilities were about $1.44 million, but the firm had negative TTM operating cash flow and free cash flow. The FY2025 auditor opinion carried a going‑concern emphasis.

The company also added a $600,000 unsecured loan at 10 percent and maintains an equity line of credit with a prior 1.65 million commitment‑fee share issuance, signaling dependence on external financing and dilution risk.